目的 探討脈血康膠囊聯(lián)合替羅非班治療老年急性冠狀動(dòng)脈綜合征的臨床療效。方法 選取2022年3月—2024年1月武漢市武昌醫(yī)院收治的急性冠狀動(dòng)脈綜合征患者94例，隨機(jī)分為對(duì)照組（47例）和治療組（47例）。對(duì)照組靜脈滴注鹽酸替羅非班注射液，溶于生理鹽水，濃度為50 μg/mL，1次/d。在對(duì)照組的基礎(chǔ)上，治療組口服脈血康膠囊，4粒/次，3次/d。兩組患者治療4周。觀察兩組患者臨床療效，比較治療前后兩組患者血管性血友病因子（vWF）、血管內(nèi)皮生長因子（VEGF）、內(nèi)皮素-1（ET-1）、循環(huán)系統(tǒng)內(nèi)皮細(xì)胞（CEC）、三酰甘油（TG）、總膽固醇（TC）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）、白細(xì)胞介素-18（IL-18）、胱抑素C（CysC）、白細(xì)胞介素-6（IL-6）和超敏C反應(yīng)蛋白（hs-CRP）指標(biāo)水平。結(jié)果 治療后，治療組的總有效率（91.49%）明顯高于對(duì)照組（74.47%，P＜0.05）。治療后，兩組患者vWF、VEGF、ET-1、CEC、TG、TC、LDL-C、IL-18、CysC、IL-6、hs-CRP指標(biāo)水平明顯降低，而HDL-C水平明顯升高（P＜0.05），且與對(duì)照組比較，治療后治療組的上述指標(biāo)水平明顯低于對(duì)照組（P＜0.05）。結(jié)論 脈血康膠囊聯(lián)合替羅非班治療老年急性冠狀動(dòng)脈綜合征效果確切，可有效改善患者缺血程度及相關(guān)癥狀，同時(shí)能減弱機(jī)體炎性反應(yīng)狀態(tài)。

Objective To explore the clinical efficacy of Maixuekang Capsules combined with tirofiban in treatment of elderly acute coronary syndrome. Methods Patients (94 cases) with elderly acute coronary syndrome in Wuhan Wuchang Hospital from March 2022 to January 2024 were randomly divided into control (47 cases) and treatment (47 cases) group. Patients in the control group were iv administered with Tirofiban Hydrochloride Injection dissolved in normal saline, 50 μg/mL, once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical evaluations were evaluated, the levels of vWF, VEGF, ET-1, CEC, TG, TC, LDL-C, HDL-C, IL-18, CysC-C, IL-6 and hs-CRP in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group (91.49%) was significantly higher than that in the control group (74.47%, P < 0.05). After treatment, the levels of vWF, VEGF, ET-1, CEC, TG, TC, LDL-C, IL-18, CysC, IL-6, and hs-CRP were significantly reduced in two groups, while the levels of HDL-C were significantly increased (P < 0.05), and compared with the control group, the levels of these indicators in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Maixuekang Capsules combined with tirofiban in treatment of elderly acute coronary syndrome has a definite effect. It can effectively improve the degree of ischemia and related symptoms of patients, and at the same time weaken the inflammatory reaction.

R972

湖北省自然科學(xué)基金資助項(xiàng)目(2022CFC022)